The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Open accessAbstract
Background: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed after ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma. Methods: Eligible patients had advanced melanoma that progressed after ICI and targeted therapy, where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) and shipped to a central good manufacturing practice facility for 22-day lifileucel manufacturing. Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Evaluation Criteria in Solid Tumors V.1.1). Results: The Full Analysis Set consisted of 153 patients treated with lifileucel, including longer-term follow-up on the 66 patients previously reported. Patients had received a median of 3.0 lines of prior therapy (81.7% received both anti-programmed cell death protein 1 and anti-cytotoxic lymphocyte-associated protein 4) and had high disease burden at baseline (median target lesion sum of diameters (SOD): 97.8 mm; lactate dehydrogenase (LDH) >upper limit of normal: 54.2%). ORR was 31.4% (95% CI: 24.1% to 39.4%), with 8 complete responses and 40 partial responses. Median duration of response was not reached at a median study follow-up of 27.6 months, with 41.7% of the responses maintained for ≥18 months. Median overall survival and progression-free survival were 13.9 and 4.1 months, respectively. Multivariable analyses adjusted for Eastern Cooperative Oncology Group performance status demonstrated that elevated LDH and target lesion SOD >median were independently correlated with ORR (p=0.008); patients with normal LDH and SOD <median had greater likelihood of response than those with either (OR=2.08) or both (OR=4.42) risk factors. The most common grade 3/4 treatment-emergent adverse events (≥30%) were thrombocytopenia (76.9%), anemia (50.0%), and febrile neutropenia (41.7%). Conclusions: Investigational lifileucel demonstrated clinically meaningful activity in heavily pretreated patients with advanced melanoma and high tumor burden. Durable responses and a favorable safety profile support the potential benefit of one-time lifileucel TIL cell therapy in patients with limited treatment options in ICI-refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Self-citationvon Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationCAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationRosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Self-citationRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
Arnold, M., Singh, D., Laversanne, M., Vignat, J., Vaccarella, S., Meheus, F., Cust, A. E., de Vries, E., Whiteman, D. C., & Bray, F. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0160 · Cited by 1,484
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz011 · Cited by 945
Self-citationImmunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Hodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Self-citationLarkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8023 · Cited by 516
Self-citationRobert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6270 · Cited by 482
Self-citationLifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T., Kluger, H. M., Thomas, S. S., Domingo-Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 451
Self-citationPollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393 · cited 2×
“26 The recurrence of irAEs following rechallenge with ICI is also a concern 27 28 ; in an analysis of patients restarting anti- PD-1 after experiencing severe irAEs on anti- PD-1 plus anti- CTLA-4 therapy, irAEs (any grade) were reported in 50% of the patients, and 30% discontinued treatment due to…”
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000398 · Cited by 291
Self-citationMaeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 269
Wu, R., Forget, M.-A., Chacon, J., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d4465 · Cited by 248
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., Lutzky, J., Higgs, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00079 · Cited by 221
Self-citationZimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 190
Self-citationLong-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Betof Warner, A., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01464 · Cited by 188
Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully
Lin, B., Du, L., Li, H., Zhu, X., Cui, L., & Li, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110873 · Cited by 181
Haanen, J., Ernstoff, M., Wang, Y., Menzies, A., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J., & Obeid, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000604 · Cited by 167
Self-citationAscierto, P. A., Bono, P., Bhatia, S., Melero, I., Nyakas, M., Svane, I. M., Larkin, J., Gomez‐Roca, C., Schadendorf, D., Dummer, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.011 · Cited by 150
Self-citationJazaeri, A. A., Zsíros, E., Amaria, R. N., Artz, A. S., Edwards, R. P., Wenham, R. M., Slomovitz, B. M., Walther, A., Thomas, S. S., Chesney, J. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2538 · Cited by 143
Self-citationSeitter, S. J., Sherry, R. M., Yang, J. C., Robbins, P. F., Shindorf, M. L., Copeland, A. R., McGowan, C. T., Epstein, M., Shelton, T. E., Langhan, M. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1171 · Cited by 125
Atkins, M. B., Lee, S. J., Chmielowski, B., Ribas, A., Tarhini, A. A., Truong, T., Davar, D., O’Rourke, M. A., Curti, B. D., Brell, J. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.36_suppl.356154 · Cited by 109
Self-citationVaupel, P., & Multhoff, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01887 · Cited by 81 · cited 1×
“39 Without sufficient quality and quantity of cells, endogenous TIL are thought to be ineffective in eliciting a robust antitumor immune response.”
Levi, S. T., Copeland, A. R., Nah, S., Crystal, J. S., Ivey, G. D., Lalani, A., Jafferji, M. S., White, B. S., Parikh, N. B., Leko, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4499 · Cited by 75
Goldinger, S. M., Buder‐Bakhaya, K., Lo, S., Forschner, A., McKean, M. A., Zimmer, L., Khoo, C. C. H., Dummer, R., Eroglu, Z., Buchbinder, E. I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.022 · Cited by 71
Self-citationPostow, M. A., Goldman, D. A., Shoushtari, A. N., Warner, A. B., Callahan, M. K., Momtaz, P., Smithy, J. W., Naito, E., Cugliari, M. K., Raber, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01570 · Cited by 61
Long, G. V., Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O'Day, S. J., Atkinson, V. G., Cebon, J. S., Brown, M. P., Dalle, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0793 · Cited by 43
Carvajal, R., Sato, T., Shoushtari, A., Sacco, J., Nathan, P., Orloff, M., Corrie, P., Steven, N., Evans, J., Infante, J., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0289-3 · Cited by 34
Self-citationMullinax, J. E., Egger, M. E., McCarter, M. D., Monk, B. J., Toloza, E. M., Brousseau, S., Jagasia, M., & Sarnaik, A. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000608 · Cited by 32
Self-citationHamid, O., Wang, D., Kim, T. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9515 · Cited by 30
Self-citationCTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Menzies, A. M., da Silva, I. P., Trojaniello, C., Vieu, E., Amaria, R. N., Zimmer, L., Lo, S. N., Burton, E. M., Tawbi, H. A., Schadendorf, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119768 · Cited by 27
Owens, G. L., Price, M. J., Cheadle, E. J., Hawkins, R. E., Gilham, D. E., & Edmondson, R. J. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2211-3 · Cited by 26
Chapman, P. B., Jayaprakasam, V. S., Panageas, K. S., Callahan, M. K., Postow, M. A., Shoushtari, A. N., Wolchok, J. D., & Warner, A. B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003395 · Cited by 18
Cybulska-Stopa, B., Rogala, P., Czarnecka, A. M., Lugowska, I. A., Teterycz, P., Galus, Ł., Rajczykowski, M., Dawidowska, A., Piejko, K., Suwiński, R., et al. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.05.005 · Cited by 17
Wagner, N. B., Lenders, M. M., Kühl, K., Reinhardt, L., André, F., Dudda, M., Ring, N., Ebel, C., Staeger, R., Zellweger, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002350 · Cited by 15
Vanderwalde, A. M., Moon, J., Kendra, K. L., Khushalani, N. I., Collichio, F. A., Sosman, J. A., Ikeguchi, A. P., Victor, A. I., Truong, T., Chmielowski, B., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-ct013 · Cited by 15
Self-citation
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03650-6 · Cited by 73
“So far, we have not observed a correlation between elevated baseline LDH leading to poor response, as was reported in other adoptive T cell 44 and checkpoint inhibitor 45,46 trials.”
Self-citation
Metadata
- Authors
- Chesney, J., Lewis, K. D., Kluger, H., Hamid, O., Whitman, E., Thomas, S., Wermke, M., Cusnir, M., Domingo-Musibay, E., Phan, G. Q., Kirkwood, J. M., Hassel, J. C., Orloff, M., Larkin, J., Weber, J., Furness, A. J. S., Khushalani, N. I., Medina, T., Egger, M. E., Graf Finckenstein, F., Jagasia, M., Hari, P., Sulur, G., Shi, W., Wu, X., & Sarnaik, A.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-12
- Volume
- 10
- Issue
- 12
- Pages
- e005755
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W4311310504
- Cited by
- 359
- References
- 49
- FWCI
- 22.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.